GO
Loading...

Enter multiple symbols separated by commas

Perrigo Co

More

  • NEW YORK/ LONDON, June 29- Mergers and acquisitions worldwide in the second quarter of 2015 almost matched the record set in the second quarter of 2007, according to preliminary Thomson Reuters data, as big companies turned to deals to boost their market share. These include Royal Dutch Shell Plc's $70 billion acquisition of British rival BG Group Plc, cable...

  • TEL AVIV, June 24- Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo Co.. Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. Perrigo's shares have been listed on TASE since it acquired Israeli...

  • Mylan eyes Tel Aviv listing if Perrigo deal goes ahead Wednesday, 24 Jun 2015 | 9:07 AM ET

    TEL AVIV, June 24- Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo Co.. Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. "Mylan believes that the Israeli market is important to Mylan and the...

  • TEL AVIV, June 23- Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co, an industry source said. Mylan has offered to acquire Perrigo for $34 billion in an attempt to fend off a bid from Israel's Teva...

  • June 16- Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend of interest from Teva Pharmaceutical Industries Ltd. Abbott, which has a 14.5 percent stake in Mylan, said on Tuesday that it supported Mylan's "standalone strategy" and believed acquiring Perrigo...

  • Abbott to vote for Mylan's acquisition of Perrigo Tuesday, 16 Jun 2015 | 9:20 AM ET

    June 16- Abbott Laboratories said it would vote its 14.5 percent stake in Mylan NV in favor of Mylan's proposed acquisition of Perrigo Company Plc. Mylan's latest offer for Perrigo, worth $34.1 billion, is widely seen as an attempt to fend off Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs. Abbott, Mylan's largest shareholder, said...

  • AMSTERDAM, June 8- Executives at Israeli drugmaker Teva sent an open letter to takeover target Mylan on Monday, saying they remain committed to a deal and reiterated that Teva's $40 billion takeover proposal would benefit shareholders of both firms. In the letter, addressed to Mylan executive founder Robert Coury, Teva CEO Erez Vigodman and Chairman Yitzhak...

  • Teva discloses 1.35 pct stake in target Mylan Wednesday, 27 May 2015 | 4:42 PM ET

    May 27- Teva Pharmaceutical Industries Ltd disclosed a 1.35 percent interest in Mylan NV, saying the purchase underscored its commitment to buy Mylan as soon as possible. Teva proposed to buy Mylan for $82 per share, or about $43 billion, in cash and stock last month. Mylan rejected the offer saying it "grossly undervalued" the company, setting up a three-way battle...

  • The company has been steadfast in its refusal to combine with Teva and is instead encouraging shareholders to support its own $34 billion unsolicited offer for over-the-counter drugmaker Perrigo Co Plc. Teva said on Tuesday it will move ahead with its plans to acquire Mylan if the Perrigo deal is not completed. Speaking privately to investors this week,...

  • *Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...

  • INTERVIEW-New-look GSK bets on consumer health spending Wednesday, 6 May 2015 | 7:19 AM ET

    LONDON, May 6- Consumers from New York to New Delhi are digging deeper in their pockets for over-the-counter remedies and health products, a trend GlaxoSmithKline is banking on to help shape the next chapter in its evolution. In the biggest shake-up in its 15- year history, GSK has just sold its cancer drugs to Novartis, while buying the Swiss group's vaccine...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland- based Perrigo Co and believes it can complete the deal by year end. Mylan, on a conference call with analysts, said it is legally committed to take its offer directly to Perrigo shareholders under Irish takeover...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland- based Perrigo Co.. "We remain steadfast in our legally binding commitment to acquire Perrigo and have taken numerous concrete steps to lay out a clear and certain path towards completion," Mylan Chief Executive...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, on Tuesday reported slightly higher-than-expected first-quarter profit and said it was "steadfast" in its commitment to acquire Ireland- based Perrigo Co.. Perrigo last week rejected a sweetened $34 billion offer from Mylan. At the same time, Mylan is attempting to fend...

  • Mylan sweetens bid for Perrigo Wednesday, 29 Apr 2015 | 10:38 AM ET
    Perrigo facility in Allegan, Michigan

    Mylan on Wednesday sweetened its bid for Perrigo.

  • Mylan raises bid for Perrigo Wednesday, 29 Apr 2015 | 9:20 AM ET
    Mylan raises bid for Perrigo

    CNBC's David Faber reports Mylan is increasing its bid for Mylan.

  • NEW YORK, April 28- A federal judge dismissed claims by former Elan Corp and Wyeth shareholders accusing billionaire investor Steven A. Cohen's SAC Capital Advisors LP of violating federal racketeering law by conducting insider trading in the drugmakers' stocks. District Judge Victor Marrero in Manhattan said the civil claims brought under the Racketeer...

  • April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's $40 billion takeover offer on Monday, saying in a scathing letter that it grossly undervalued the company and that Mylan has no interest in payment in what it termed "high-risk" Teva stock. Mylan shares fell 5.7 percent to $71.71 on Nasdaq, and Teva fell 3.8 percent to $61.93 on the New York Stock...

  • April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer on Monday, saying it was too low and calling Teva stock an "unacceptable" currency. Mylan, which is pursuing its own takeover of Perrigo Co Plc, had been expected to reject the offer after having indicated that such a combination would not be a good fit.

  • April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer on Monday, but left the door open for talks. Mylan also said it remained committed to its offer for Perrigo Co Plc. Last week, Mylan said it would take its $31 billion offer for Perrigo directly to shareholders, in what is set to be one of the most high-profile...